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Chemical signaling has a key role in neural and non-neu-
ral function; however, only a few techniques are available
to measure the concentrations of neurotransmitters and
modulators directly in the extracellular space. A recent
advance in this area is the development of the multi-enzy-
matic microelectrode biosensor technique whereby we
can measure the concentration of different neurotransmit-
ters and modulators around single neurons or synaptic
structures in the brain with high temporal and spatial res-
olution. Micro-biosensors are also ideal for detecting real-
time neurotransmitter release in the central nervous sys-
tem in vivo because they are minimally invasive. The ATP
biosensor is formed by coating a Pt microelectrode with
an ultrathin biolayer containing glycerol kinase and glyc-
erol-3-phosphate oxidase, which results in the production
of electroactive H2O2, detected by amperometry. The null
sensor, which possesses the silicate layer but lacks the
enzymes, shows near-identical responses to the interfer-
ences potentially allowing the use of differential record-
ings to remove almost all of the interfering signals. We
used the ATP microelectrode biosensor to demonstrate
the release of ATP from rat hippocampal slices in vitro.
The basal ATP levels have been estimated to be as low as a
few nmol/L (25 ± 5 pA). The ATP sensor exhibited a rap-
idly increasing current during K+ depolarization which
reached 341 ± 170 pA (peak concentration 0.79 ± 0.2
μmol/L). This effect was significantly decreased by the Na+
channel blocker TTX (0.17 ± 0.08 μmol/L) and by Ca2+-
free medium (0.22 ± 0.1 μmol/L).
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